Routine magnetoencephalography in memory clinic patients: A machine learning approach.
Alzheimer's disease
diagnostic biomarker
machine learning
magnetoencephalography
random forest classifier
Journal
Alzheimer's & dementia (Amsterdam, Netherlands)
ISSN: 2352-8729
Titre abrégé: Alzheimers Dement (Amst)
Pays: United States
ID NLM: 101654604
Informations de publication
Date de publication:
2021
2021
Historique:
received:
20
03
2021
revised:
12
05
2021
accepted:
04
06
2021
entrez:
27
9
2021
pubmed:
28
9
2021
medline:
28
9
2021
Statut:
epublish
Résumé
We report the routine application of magnetoencephalography (MEG) in a memory clinic, and its value in the discrimination of patients with Alzheimer's disease (AD) dementia from controls. Three hundred sixty-six patients visiting our memory clinic underwent MEG recording. Source-reconstructed MEG data were visually assessed and evaluated in the context of clinical findings and other diagnostic markers. We analyzed the diagnostic accuracy of MEG spectral measures in the discrimination of individual AD dementia patients (n = 40) from subjective cognitive decline (SCD) patients (n = 40) using random forest models. Best discrimination was obtained using a combination of relative theta and delta power (accuracy 0.846, sensitivity 0.855, specificity 0.837). The results were validated in an independent cohort. Hippocampal and thalamic regions, besides temporal-occipital lobes, contributed considerably to the model. MEG has been implemented successfully in the workup of memory clinic patients and has value in diagnostic decision-making.
Identifiants
pubmed: 34568539
doi: 10.1002/dad2.12227
pii: DAD212227
pmc: PMC8449227
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e12227Informations de copyright
© 2021 The Authors. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring published by Wiley Periodicals, LLC on behalf of Alzheimer's Association.
Déclaration de conflit d'intérêts
A.A. Gouw has received past (2014‐2018) research support from Probiodrug and Boehringer Ingelheim via the VUmc Alzheimer Center. P. Scheltens has received consultancy fees (paid to the institution) from AC Immune, Alkermes, Alnylam, Alzheon, Anavex, Biogen, Brainstorm Cell, Cortexyme, Denali, EIP, ImmunoBrain Checkpoint, GemVax, Genentech, Green Valley, Novartis, Novo Nordisk, PeopleBio, Renew LLC, and Roche. He is principal investigator of studies with AC Immune, CogRx, FUJI‐film/Toyama, IONIS, UCB, and Vivoryon. He is a part‐time employee of Life Sciences Partners Amsterdam. He serves on the board of Brain Research Center and New Amsterdam Pharma.
Références
Front Neurosci. 2016 Feb 23;10:47
pubmed: 26941594
Front Hum Neurosci. 2016 May 20;10:238
pubmed: 27242496
Brain. 2016 Jul;139(Pt 7):1877-90
pubmed: 27190025
Dement Geriatr Cogn Disord. 2003;15(2):106-14
pubmed: 12566600
Front Hum Neurosci. 2019 Feb 05;13:17
pubmed: 30792632
Dement Geriatr Cogn Disord. 2011;31(3):195-201
pubmed: 21430383
J Neural Eng. 2012 Jun;9(3):036007
pubmed: 22571870
Neurology. 2017 Jul 4;89(1):88-100
pubmed: 28592453
Clin EEG Neurosci. 2014 Apr;45(2):104-12
pubmed: 24131618
Alzheimers Dement. 2018 Apr;14(4):535-562
pubmed: 29653606
Dement Geriatr Cogn Disord. 2009;27(1):18-23
pubmed: 19088474
PLoS One. 2013;8(3):e59856
pubmed: 23527277
Nat Neurosci. 2015 Nov;18(11):1623-30
pubmed: 26457554
Neuroimage Clin. 2015 Aug 01;9:103-9
pubmed: 26448910
Brain. 2011 Sep;134(Pt 9):2456-77
pubmed: 21810890
Brain. 2008 Mar;131(Pt 3):690-705
pubmed: 18202105
Neurology. 2020 Aug 11;95(6):e662-e670
pubmed: 32636325
Clin Neurophysiol. 2017 Oct;128(10):2058-2067
pubmed: 28866471
J Alzheimers Dis. 2018;64(4):1359-1371
pubmed: 29991135
Alzheimers Dement (Amst). 2019 Jun 14;11:450-462
pubmed: 31431918
J Alzheimers Dis. 2011;26 Suppl 3:201-14
pubmed: 21971461
Clin Neurophysiol. 2018 Aug;129(8):1720-1747
pubmed: 29724661
Alzheimer Dis Assoc Disord. 2014 Jul-Sep;28(3):206-18
pubmed: 24632990
Clin Neurophysiol. 2016 Aug;127(8):2766-2769
pubmed: 27417050
Neuroimage. 2002 Jan;15(1):273-89
pubmed: 11771995
Front Neurosci. 2017 Jan 26;10:604
pubmed: 28184183
Int J Psychophysiol. 2002 Oct;46(1):53-66
pubmed: 12374646
Elife. 2019 Apr 30;8:
pubmed: 31038453
Proc Natl Acad Sci U S A. 2016 Apr 5;113(14):3867-72
pubmed: 27001844
Clin Neurophysiol. 2018 Aug;129(8):1709-1711
pubmed: 29903504
Artif Intell Med. 2008 May;43(1):75-85
pubmed: 18329868
Front Comput Neurosci. 2018 Aug 23;12:60
pubmed: 30190674
Neurobiol Aging. 2017 Sep;57:133-142
pubmed: 28646686
Alzheimers Res Ther. 2019 Jun 1;11(1):49
pubmed: 31151467
J Neurol Sci. 2009 Aug 15;283(1-2):127-33
pubmed: 19268969
Alzheimers Dement (Amst). 2016 Aug 19;4:99-106
pubmed: 27722196
Curr Opin Psychiatry. 2010 May;23(3):273-7
pubmed: 20216218
Neurobiol Aging. 2011 Apr;32(4):563-71
pubmed: 20022139
Hum Brain Mapp. 2019 Mar;40(4):1353-1375
pubmed: 30378210
Alzheimers Dement. 2014 Nov;10(6):713-723.e2
pubmed: 24721526
Ann Biomed Eng. 2009 Mar;37(3):586-94
pubmed: 19130227
IEEE Trans Biomed Eng. 2019 Oct;66(10):2924-2935
pubmed: 30762522
Clin Neurophysiol. 2004 Jul;115(7):1490-505
pubmed: 15203050
Clin Neurophysiol. 2015 Sep;126(9):1735-9
pubmed: 25534493
J Alzheimers Dis. 2014;41(1):313-27
pubmed: 24614907
Front Aging Neurosci. 2018 Jul 03;10:190
pubmed: 30018548
Brain. 2018 May 1;141(5):1470-1485
pubmed: 29522156
Alzheimers Dement. 2011 May;7(3):263-9
pubmed: 21514250
Neurobiol Aging. 2012 May;33(5):1008.e25-31
pubmed: 22118944